<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594058</url>
  </required_header>
  <id_info>
    <org_study_id>VEL-2001</org_study_id>
    <nct_id>NCT03594058</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)</brief_title>
  <acronym>VEL-2001</acronym>
  <official_title>A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Oral Solabegron Modified Release Tablets in the Treatment of Overactive Bladder (OAB) in Adult Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Velicept Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Velicept Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group
      study designed to evaluate the efficacy, safety, and tolerability of solabegron modified
      release low dose or high dose tablets, compared to matched placebo, administered once daily
      for 12 weeks to adult female subjects with overactive bladder symptoms (frequency, urgency,
      and predominantly urgency incontinence) for at least 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Actual">May 2, 2019</completion_date>
  <primary_completion_date type="Actual">April 29, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Eligible female subjects (N=1200) with symptoms of overactive bladder for at least 6 months will enter a 14-day single-blind Run-in Period. Subjects (N=375) who meet prespecified criteria based on data entered into an electronic diary over 3 days will be randomized 1:1:1 (125 subjects per arm) to receive solabegron modified release tablets, low dose or high dose, or matching placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Sponsor representatives Site monitors Data managers Statistician</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in mean number of micturitions per 24 hours at Week 12</measure>
    <time_frame>Micturtions will be assessed prior to randomization and at Week 12 (Visit 6).</time_frame>
    <description>Micturition events will be recorded by subjects in an eDiary using a smartphone device during 3-day diary periods prior to randomization and at 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Incontinence (1)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Change from Baseline in mean number of urgency urinary incontinence episodes per 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Incontinence (2)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Percentage change from Baseline in mean number of urgency urinary incontinence episodes per 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Incontinence (3)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Proportion of subjects with no episodes of urgency urinary incontinence per 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Incontinence (4)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Proportion of subjects with no episodes of urinary incontinence (urgency and non-urgency) per 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Incontinence (5)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Change from Baseline in total urinary incontinence episodes (urgency and non-urgency) per 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Micturitions (1)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4 and 8</time_frame>
    <description>Change from Baseline in mean number of micturitions per 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Micturitions (2)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Percentage change from Baseline in mean number of micturitions per 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Micturitions (3)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Percentage of subjects with &lt; 8 micturitions per 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Micturitions (4)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Change from Baseline in mean number of nocturnal voids per 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Void Volume (1)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Change from Baseline in average void volume over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Void Volume (2)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Percentage change from Baseline in average void volume over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Void Volume (3)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Change from Baseline in maximum individual void volume over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Void Volume (4)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Percentage change from Baseline in maximum individual void volume over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgency (1)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Proportion of subjects with urges with a mean grade of 3 of 4 per 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgency (2)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Change from Baseline in mean urgency assessments per 24 hours associated with micturitions or incontinence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes (1)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Patient Perception of Bladder Control. This patient-reported questionnaire assesses the patient's perception of current urinary problems, where higher score (on a scale of 1 to 6) indicates more severe problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes (2)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Change from Baseline in Symptom Bother Score (Overactive Bladder Questionnaire [OAB-q] short form). The OAB-q short form is completed as a 4-week recall where a higher score (on a scale of 1 to 6) indicates greater symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes (3)</measure>
    <time_frame>Prior to Randomization (Baseline) and at Weeks 4, 8, and 12</time_frame>
    <description>Change from Baseline in health-related quality of life (Overactive Bladder Questionnaire [OAB-q] short form). The OAB-q short form is completed as a 4-week recall where a higher score (on a scale of 1 to 6) indicates worse health-related quality of life.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1413</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Solabegron modified release tablets low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Solabegron modified release tablets high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solabegron modified release tablets, low dose</intervention_name>
    <description>Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.</description>
    <arm_group_label>Solabegron modified release tablets low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solabegron modified release tablets, high dose</intervention_name>
    <description>Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.</description>
    <arm_group_label>Solabegron modified release tablets high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult female subjects 18 to 80 years of age, with a ≥ 6-month history of symptoms of
             overactive bladder including: frequency, urgency, urgency urinary incontinence, and
             mixed incontinence. Subjects must provide written informed consent and either be of
             non-childbearing potential or of childbearing potential meeting specific criteria
             (e.g., negative pregnancy test, sexual inactivity, acceptable methods of birth
             control, and use of hormonal contraceptives).

        Exclusion Criteria:

          -  Subjects must have no history of pelvic or bladder disease, e.g., uterine prolapse,
             malignancy, prior surgery, or treatment with botulinum toxin.

          -  Diabetes insipidus or poorly controlled Type 1 or Type 2 diabetes mellitus

          -  Cardiac conditions:

          -  prior cardiovascular events or procedures within 6 months of screening

          -  congestive heart failure

          -  abnormal ECG findings, including ECG QT correction interval (QTc) &gt; 470 msec at the
             Screening Visit

          -  systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg, or heart
             rate &gt; 100 beats per minute

          -  Abnormal tests of liver function

          -  History of prior infection due to HIV or hepatitis B or hepatitis C virus

          -  Allergy or hypersensitivity to solabegron or mirabegron

          -  Women of childbearing potential: breastfeeding, pregnant, or actively trying to become
             pregnant

          -  Participation in a trial of an investigational or marketed drug ≤ 30 days prior to the
             Screening Visit or in any clinical trial of an investigational drug that may affect
             urinary function within 3 months prior to Screening Visit.

          -  Inability to read, understand, or complete study-related materials
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Velicept Investigative Site - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Guntersville</name>
      <address>
        <city>Guntersville</city>
        <state>Alabama</state>
        <zip>35976</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Saraland</name>
      <address>
        <city>Saraland</city>
        <state>Alabama</state>
        <zip>36571</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Lincoln</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - North Hollywood</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Spring Valley</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Upland</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Englewood</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - New London</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Aventura</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Doral(2)</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Doral</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Edgewater</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Hialeah</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Hollywood</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Lauderdale Lakes</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Miami Springs</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - New Port Richey</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Palm Harbor</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Pompano Beach</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - West Palm Beach</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Snellville</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Crowley</name>
      <address>
        <city>Crowley</city>
        <state>Louisiana</state>
        <zip>70526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Metairie</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Brighton</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - North Dartmouth</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Saginaw</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Biloxi</name>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <zip>39531</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Olive Branch</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <zip>38654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - La Vista</name>
      <address>
        <city>La Vista</city>
        <state>Nebraska</state>
        <zip>68128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Edison</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08837</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Fargo</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Dayton</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Mustang</name>
      <address>
        <city>Mustang</city>
        <state>Oklahoma</state>
        <zip>73064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Oklahoma City</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Gresham</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Lansdale</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - East Providence</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Lincoln</name>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <zip>02865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Charleston</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Charleston</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Fort Mill</name>
      <address>
        <city>Fort Mill</city>
        <state>South Carolina</state>
        <zip>29707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Spartanburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Jackson</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37938</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Bryan</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Carrollton</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Georgetown</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Plano(1)</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Plano(2)</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - San Angelo</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velicept Investigative Site - Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012 Nov;62(5):834-40. doi: 10.1016/j.eururo.2012.05.053. Epub 2012 Jun 5.</citation>
    <PMID>22695239</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <disposition_first_submitted>February 27, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>February 27, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 2, 2020</disposition_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>overactive bladder</keyword>
  <keyword>urinary conditions</keyword>
  <keyword>urgency urinary incontinence</keyword>
  <keyword>urgency</keyword>
  <keyword>micturitions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solabegron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

